The European Medicines Agency has emerged as the second major regulatory venue shaping the global peptide therapeutics landscape, often setting precedents the FDA later mirrors. The EMA approved semaglutide as the first GLP-1 receptor agonist with a formal cardiovascular and stroke benefit indication (March 27, 2026), and granted a CHMP positive opinion for the Wegovy pill (oral semaglutide 25 mg) on May 22, 2026, paving the way for EU launches in H2 2026 carrying the SELECT MACE-reduction labeling. Oncopeptides filed a Type II variation in May 2026 to expand the Pepaxti (melflufen) peptide-drug conjugate label to third-line multiple myeloma — one of only two FDA/EMA-approved peptide-drug conjugates currently on market alongside Novartis's Lutathera.
The agency's first-ever dedicated 'Guideline on the Development and Manufacture of Synthetic Peptides' (EMA/CHMP/CVMP/QWP/367182/2025) became legally effective June 1, 2026, covering manufacturing routes, peptide-specific impurity types, pooling strategy in preparative chromatography, comparability requirements, and analytical control for both human and veterinary synthetic peptide APIs. Biological peptides produced by recombinant technology and radiopharmaceuticals fall outside the scope. The standard arrives on the same regulatory calendar as the FDA's July 23-24 PCAC peptide reclassification review and the May 2026 EU CHMP Wegovy pill opinion.
Stories here cover CHMP scientific opinions, EU marketing authorizations, EMA pharmacovigilance signals, and the diverging or converging US-EU regulatory paths for peptide therapeutics. See [[wegovy]], [[semaglutide]], [[regulatory]], and [[manufacturing]] for adjacent threads.
The European Medicines Agency's first-ever dedicated 'Guideline on the Development and Manufacture of Synthetic Peptides' (EMA/CHMP/CVMP/QWP/367182/2025) entered into force June 1, 2026 after adoption by CHMP on December 1, 2025 and CVMP on December 4, 2025. The guideline applies to both new and existing synthetic peptide active substances used in human and veterinary medicines, including investigational medicinal products and post-authorisation changes, and covers manufacturing routes, peptide-specific impurity types, pooling strategy in preparative chromatography, comparability requirements, characterization, specifications, and analytical control. Biological peptides produced by recombinant technology and radiopharmaceuticals are excluded. The standard arrives on the same regulatory calendar as the FDA's PCAC peptide reclassification review (July 23-24, 2026) and the FDA's 503B GLP-1 bulks exclusion comment window (closes June 29).
Oncopeptides AB announced May 11-12 it intends to submit a Type II variation application to the European Medicines Agency to expand the Pepaxti (melflufen) label to include third-line treatment of relapsed/refractory multiple myeloma. Pepaxti is one of two FDA-approved peptide-drug conjugates currently on market (the other being Novartis's 177Lu-dotatate Lutathera) and acts as a melphalan-flufenamide alkylating peptide that exploits aminopeptidase enzymes overexpressed in myeloma plasma cells to selectively release the cytotoxic payload inside tumor cells. The Pepaxti EMA label currently covers heavily pre-treated (≥4 prior lines) RRMM; the new third-line expansion submission would meaningfully extend the eligible population. The filing positions the PDC modality for a broader regulatory footprint as the broader peptide-drug-conjugate field heads into ASCO 2026.
The European Medicines Agency formally approved semaglutide with cardiovascular and stroke-related benefits — a first for any GLP-1 receptor agonist in Europe.